Mice lacking protein tyrosine kinase fyn develop a T helper-type 1 response and resistLeishmania major infection

K Yamakami1, S Akao, K Wakabayashi

  • 1Department of Public Health, National Defense Medical College, 3-2 Namiki, 359-8513, Tokorozawa, Saitama, Japan, yamakami@cc.ndme.ac.jp.

Insights

Mice lacking Fyn tyrosine kinase remained resistant to Leishmania major infection, showing normal T helper-type 1 (Th1) responses. This suggests Fyn plays a minor role in the immune defense against leishmaniasis.

Area of Science:

  • Immunology
  • Molecular Biology
  • Biochemistry

Background:

  • Fyn is a Src family protein tyrosine kinase crucial for T cell activation, calcium flux, and IL-2 production.
  • The protective immune response against Leishmania major infection involves T helper-type 1 (Th1) responses and cytokines like IL-2 and interferon-gamma.

Purpose of the Study:

  • To investigate the in vivo role of Fyn tyrosine kinase in the immune response to Leishmania major infection.
  • To determine if Fyn deficiency impacts resistance and Th1 responses in mice infected with Leishmania major.

Main Methods:

  • Utilized C57BL/6fyn-deficient mice to examine the in vivo role of Fyn.
  • Assessed resistance to Leishmania major infection by monitoring lesion development.
  • Evaluated Th1 responses through delayed-type hypersensitivity and cytokine analysis.

Main Results:

  • Fyn-deficient mice exhibited resistance to Leishmania major infection with only mild lesion development.
  • These mice maintained robust Th1 responses, including delayed-type hypersensitivity and appropriate cytokine production.
  • The in vivo findings did not correlate with the anticipated in vitro functions of Fyn in T cell activation.

Conclusions:

  • Fyn tyrosine kinase appears to play a minor role in the protective immune response against Leishmania major infection.
  • Fyn is not a key factor in the host's defense mechanisms against leishmaniasis.
  • The in vitro functions of Fyn may not directly translate to its role in vivo during leishmanial disease.